Bristol educational outreach for Excedrin Migraine targeted to serious headache sufferers.
This article was originally published in The Tan Sheet
Executive Summary
BRISTOL EDUCATIONAL OUTREACH FOR EXCEDRIN MIGRAINE will be directed at consumers who want to learn more about serious headaches that may be migraines. Bristol-Myers Squibb estimates that upwards of 25 mil. Americans, mostly women (75%) and those in their 30s, suffer from headaches that could be classified as migraines, and that an estimated 17 mil. of those headache sufferers do not seek professional treatment. FDA's estimates of migraine sufferers are slightly lower, at 16 mil. to 18 mil., nonetheless, a large potential customer base for Excedrin Migraine.